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Introduction {#sec1}
============

High-affinity germinal center (GC)-derived antibodies are crucial for protection from many pathogens. During a T-cell-dependent response, antigen-reactive B cells are selected for entry into the GC by CD4^+^ T cells. The earliest T cell selection of the B cell occurs at the T-B border 1--2 days after antigen exposure. After 3--6 days, T cells residing in the GC, termed T follicular helper (Tfh) cells, are required to select GC B cells. Most data favor a model for high-affinity B cell selection where cells with improved affinity internalize and present more of the antigen and win out in receiving more or better-quality T cell help through CD40 ligand (CD40L) or other signals ([@bib2], [@bib39]). However, which factors beyond major histocompatibility complex (MHC) class II-peptide amounts determine the quantity and quality of help delivered to GC B cells is incompletely understood.

The tumor necrosis factor (TNF) receptor superfamily member HVEM (encoded by the gene *TNFRSF14*) is the most highly mutated surface molecule in GC-derived follicular lymphoma (FL) and diffuse large B cell lymphoma (DLBCL) ([@bib13], [@bib32], [@bib33], [@bib37], [@bib51]). HVEM is expressed in B cells as well as several other cell types and has multiple ligands. Two ligands, LIGHT and LTα3, are members of the TNF superfamily, whereas two other ligands, BTLA and CD160, are members of the immunoglobulin (Ig) superfamily. BTLA and CD160 bind HVEM's first cysteine-rich domain (CRD1), whereas LIGHT binds CRD2 ([@bib64]). HVEM contains TRAF-binding motifs in its cytoplasmic tail, and cross-linking of HVEM can lead to downstream signaling via NFκB ([@bib12], [@bib24], [@bib57]). In addition to acting as a receptor and transducing intracellular signals, HVEM can act as a ligand and transmit signals into BTLA-expressing cells ([@bib53]).

BTLA is widely expressed by immune cells and is highly expressed on B cells, dendritic cells (DCs), and some effector T cells ([@bib41]). BTLA contains ITIM (immunoreceptor tyrosine-based inhibition) motifs in its cytoplasmic domain and can recruit both SH2-domain-containing tyrosine phosphatases SHP1 and SHP2, but not SHIP or SAP ([@bib9], [@bib22], [@bib58], [@bib65]). BTLA can negatively regulate both T cell receptor (TCR) and B cell receptor (BCR) signaling *in vitro* ([@bib60], [@bib66]) and can be recruited to the immune cell interface ([@bib44]). BTLA also contains a Grb2 binding site that might promote CD8^+^ T cell cytokine production and proliferation ([@bib48], [@bib62]). Therefore, the signaling actions of BTLA might differ between different cell populations and need to be defined on a cell-type-by-cell-type basis.

BTLA is a Tfh cell marker, yet its role in these cells is not well defined ([@bib15], [@bib42]). In one study, *Btla*^−/−^ T cells supported a slightly greater IgG2a and IgG2b response following OVA immunization ([@bib28]). In a recent study, small hairpin RNA (shRNA) targeting of *Hvem* in a Bcl-2-driven model of FL increased lymphomagenesis ([@bib4]). Hematopoietic shRNA targeting of *Btla* also increased lymphomagenesis, and the authors suggest that this reflects a function of HVEM within B cells engaging BTLA in B cells to transmit BTLA-mediated BCR-repressive signals. Whether such signals occur in normal GC B cells remains unclear.

Here, we found that HVEM acts to restrain B cell participation in the GC response by signaling via BTLA on T cells. HVEM deficiency provided a proliferative advantage to B cells as early as day 3 or 4 of the response. HVEM engagement of BTLA on T cells decreased TCR signaling and the amount of preformed CD40L mobilized to the T cell surface. Thus, HVEM on B cells restrains T cell help to influence GC selection outcomes, and interfering with this regulatory axis provides a competitive advantage in GC B cell lymphomagenesis.

Results {#sec2}
=======

HVEM Deficiency Increases GC B Cell Competitiveness {#sec2.1}
---------------------------------------------------

*Hvem* (*Tnfrsf14*) transcripts were expressed at similar levels in follicular and GC B cells ([Figure 1](#fig1){ref-type="fig"}A), and HVEM was present on the surface of both cell types, though at lower levels on GC B cells ([Figure 1](#fig1){ref-type="fig"}B). To test whether HVEM is an intrinsic regulator of GC B cell responses, we generated mixed-bone-marrow (BM) chimeric mice where BM from wild-type (WT) CD45.1 donor mice was mixed with CD45.2 BM from *Hvem*^+/−^ or *Hvem*^−/−^ mice. After immunization with sheep red blood cells (SRBCs), HVEM-deficient B cells were represented more in GCs than in the follicular compartment ([Figure 1](#fig1){ref-type="fig"}C and [Figure S1](#mmc1){ref-type="supplementary-material"}A). HVEM heterozygosity led to an intermediate phenotype ([Figure 1](#fig1){ref-type="fig"}C). The participation of *Hvem*^−/−^ B cells in the follicular compartment matched that of developing B cells in the BM ([Figure S1](#mmc1){ref-type="supplementary-material"}B). HVEM deficiency also provided GC B cells with increased competitiveness in chronic GCs in the mesenteric lymph node and Peyer's patches ([Figure S1](#mmc1){ref-type="supplementary-material"}C). *Hvem*^−/−^ B cells were similarly over-represented in the light and dark zones of the GC ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Although HVEM deficiency gave GC B cells a competitive advantage in the mixed setting, it did not lead to a significant increase in GC size in competitive or non-competitive conditions ([Figures S1](#mmc1){ref-type="supplementary-material"}E and S1F).Figure 1HVEM Deficiency Increases GC B Cell Competitiveness(A) Quantitative PCR analysis of *Hvem* (*Tnfrsf14*) transcript abundance, relative to *Ptprc* abundance, in follicular (Fo) and GC B cells.(B) Representative flow-cytometric analysis of HVEM surface expression on *Hvem*^+/+^ Fo and GC B cells compared with *Hvem*^−/−^ cells.(C) Contribution of *Hvem*^+/+^, *Hvem*^+/−^, and *Hvem*^−/−^ CD45.2 cells to Fo and GC B cell populations in the spleen of mixed BM chimeras made with ∼30% CD45.2 and ∼70% WT CD45.1 BM at day 8 after SRBC immunization. Data are representative of more than three independent experiments.(D) Ratio of *Hvem*^+/+^ or *Hvem*^−/−^ NP^+^ or NP^−^ CD45.2 GC cells to total CD45.2 Fo B cells in mixed BM chimeras after NP-CGG alum immunization at days 6--21 of the splenic response. Data are shown as ratios to simplify varied mixing of ∼20%--50% CD45.2 and ∼80%--50% CD45.1 BM across experiments. Data are pooled from more than five experiments.(E) MIXCR BCR repertoire analysis of Ig light-chain V gene usage from paired-end bulk RNA sequencing on fluorescence-activated cell sorting (FACS)-sorted GC B cells from *Hvem*^−/−^ CD45.2 (n = 3) and WT CD45.1 (n = 3) from the same mixed BM chimeras at day 11 after NP-CGG alum immunization.(F) Frequency of W33L mutations in the V~H~186.2 heavy chain from sorted CD45.2 *Hvem*^+/+^ or *Hvem*^−/−^ cells and CD45.1 WT GC B cells at days 11--13 after NP-CGG immunization of mixed BM chimeras. Data are pooled from five experiments.Unpaired Student's t test (A, C, and D) or chi-square and Fischer's exact test (E and F): ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. Bars indicate mean ± SD. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

To permit tracking of antigen-specific B cells during the GC response, we immunized mixed BM chimeras with the haptenated antigen NP-CGG in alum adjuvant. In the GC response at day 6 or 7 after immunization, HVEM-deficient B cells were more frequent in GCs than in the follicular compartment ([Figure 1](#fig1){ref-type="fig"}D). Notably, this advantage was more pronounced in the non-hapten binding (NP^−^) GC B cells than in the NP^+^ fraction ([Figure 1](#fig1){ref-type="fig"}D). HVEM-deficient GC B cells maintained approximately the same magnitude of advantage over the course of the GC response through day 21 ([Figure 1](#fig1){ref-type="fig"}D). The frequency of NP^+^ GC B cells was similar between full *Hvem*^−/−^ animals and WT littermate controls, suggesting that there is not a baseline repertoire difference ([Figures S1](#mmc1){ref-type="supplementary-material"}G and S1H).

Paired-end RNA sequencing and BCR gene-usage analysis through MIXCR ([@bib6]) at day 11 of the response showed that *Hvem*^−/−^ GC B cells used *Iglv1*, the canonical λ chain expanded during NP responses in C57BL/6 mice, less than their WT competitors ([Figure 1](#fig1){ref-type="fig"}E). We performed PCR on sorted GC B cells from mixed BM chimeras to examine the frequency of high-affinity mutations in the canonical NP-responding gene *VH186.2* at days 11--13. When referenced against the WT mixed chimeras, HVEM-deficient GC B cells had a lower stringency in selection for the W33L mutation than WT GC B cells in the same animal ([Figure 1](#fig1){ref-type="fig"}F).

The SRBC-immunized mixed BM chimeras showed more HVEM-deficient than WT memory B (Bmem) cells and plasma cells (PCs) at day 8 ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1I). HVEM deficiency also increased the frequency of NP^+^ Bmem cells and PCs at days 7--21 of the NP-CGG response ([Figure S1](#mmc1){ref-type="supplementary-material"}J). These data suggest that Bmem cells and PCs were generated approximately in proportion to the GC cells. Additionally, HVEM deficiency did not affect the frequency of IgG1^+^ class-switched B cells in the GC ([Figure S1](#mmc1){ref-type="supplementary-material"}K). One mechanism by which HVEM deficiency could lead to increased GC B cell accumulation is by reduced cell death. However, the frequencies of apoptotic HVEM-deficient and WT GC B cells as measured by active caspase-3 were similar ([Figure S1](#mmc1){ref-type="supplementary-material"}L). These findings led us to consider whether B cell proliferation might be affected.

HVEM Deficiency Provides the Earliest GC B Cells with a Proliferation Advantage {#sec2.2}
-------------------------------------------------------------------------------

To determine whether HVEM deficiency increases B cell entry into the GC, we crossed the *Hvem*^−/−^ mouse line to the Hy10 mouse line, which has a BCR specific to hen egg lysozyme (HEL). To test whether *Hvem*^−/−^ B cells proliferate more than their competitors during the early response, we labeled *Hvem*^−/−^ and WT Hy10 B cell mixes with cell trace violet (CTV), co-transferred them with OVA-specific OT-II CD4^+^ T cells into WT hosts, and immunized the mice with HEL-OVA or the lower-affinity antigen DEL-OVA ([Figure 2](#fig2){ref-type="fig"}A). At day 2, the amount of proliferation in each group was similar, but by day 3, *Hvem*^−/−^ Hy10 B cells had an increased frequency of cells that had divided greater than four times, as measured by the increase in CTV^lo^ cells ([Figures 2](#fig2){ref-type="fig"}B and 2C). The responses to high- and low-affinity forms of the antigen were similar ([Figure 2](#fig2){ref-type="fig"}C). When the proliferation rates were referenced against those in the control mixed transfers, the proliferation rate of the WT cells that were in competition with the HVEM-deficient cells appeared decreased ([Figure 2](#fig2){ref-type="fig"}C). At days 4.5--5 after immunization, when both plasmablasts (PBs) and GC B cells could be clearly identified by flow cytometry ([Figure S2](#mmc1){ref-type="supplementary-material"}A), *Hvem*^−/−^ Hy10 B cells were more frequent in the GC compartment than their WT competitors ([Figure 2](#fig2){ref-type="fig"}D). There was also an increase in the PB compartment, though this effect was often not as marked as for the GC B cells in the same animals ([Figure 2](#fig2){ref-type="fig"}D). These data suggest that HVEM deficiency reveals itself in a competitive environment by allowing *Hvem*^−/−^ B cells to outcompete the ability of WT B cells to proliferate.Figure 2HVEM Deficiency Provides B Cells with a Proliferation Advantage Early in the Response and within the GC(A) Experimental scheme and timeline for experiments in (B)--(D). CD45.1/2 indicates cells from mice carrying both a CD45.1 and a CD45.2 allele. SAS indicates Sigma Adjuvant System.(B) Representative CTV dilution at 48 and 72 hr of Hy10 B cells compared with co-transferred WT Hy10 B cells after DEL-OVA immunization. *Hvem*^+/+^ or *Hvem*^−/−^ Hy10 is in red, and WT mixing partner (control) is in blue.(C) Frequency of CTV-diluted (defined as more than three divisions at 48 hr and more than four divisions at 72 hr) Hy10 B cells compared with their WT mixing controls. Gray circles indicate HEL-OVA immunization, and red circles indciate DEL-OVA immunization. Data are pooled from three experiments.(D) Ratio of the frequency of GFP^+^HEL^+^ GC B cells or PBs at days 4.5--5 after HEL-OVA immunization to the pre-transfer frequency of GFP^+^HEL^+^ B cells. Data are pooled from three experiments with pre-transfer mixtures of ∼20%--60% GFP^+^ cells.(E) Mixed Hy10 transfer with endogenous T cell response into *Bcl6*^f/f^*Cd4*^Cre^ hosts and 2×-HEL SRBC immunization. The ratio of the frequency of CD45.1/2 *Hvem*^+/+^ or *Hvem*^−/−^ Hy10 to the pre-transfer frequency is shown. Tfh-cell-deficient (*Bcl6*^f/f^*Cd4*^Cre^) and control hosts were analyzed at days 5--7. Data are pooled from three experiments.(F) Experimental scheme and timeline for experiments in (G).(G) Frequency of CD45.2 Fo and GC B cells in the tamoxifen-treated mixed BM chimeras. Data are pooled from three experiments and include chimeras with 10%--60% CD45.2 Fo B cells.(H) Frequency of EdU^+^IgD^lo^EphrinB1^+^ GC B cells in *Hvem*^+/+^ and *Hvem*^−/−^ mixed BM chimeras immunized with NP-CGG. Animals were treated with EdU 1 hr before analysis at day 6 or 7 (black circles) and day 21 (red circles). Data are pooled from three experiments.Unpaired two-tailed Student's t test (C--E and G) or paired two-tailed Student's t test (H): ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Loss of HVEM in an Ongoing GC Provides B Cells with a Competitive Advantage {#sec2.3}
---------------------------------------------------------------------------

Tfh cells are involved in supporting the early steps in GC induction as well as the mature GC response. To test whether the growth advantage of HVEM-deficient B cells requires Tfh cells, we transferred *Hvem*^−/−^ and WT Hy10 B cell mixtures into Tfh-cell-deficient *Bcl6*^f/f^ *Cd4*^Cre^ hosts. At days 5--7 after immunization with 2×-HEL-SRBC (an intermediate-affinity HEL conjugated to SRBCs), Hy10 B cells expanded in both control and *Bcl6*^f/f^ *Cd4*^Cre^ hosts ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Although *Hvem*^−/−^ Hy10 B cells were more frequent than their WT competitors in control hosts, the HVEM-deficient advantage was lost in the Tfh-cell-deficient hosts ([Figure 2](#fig2){ref-type="fig"}E).

To determine whether HVEM deficiency provides B cells with a competitive growth advantage once the cells are within the GC, we crossed *Hvem*-floxed CD45.2 animals to the inducible GC Cre line, *S1pr2*^ERT2Cre^, and to tdTomato^f/f^ reporter animals. We then made mixed BM chimeras with the *Hvem*-floxed line and respective controls, immunized with NP-CGG and treated with tamoxifen at day 3 to activate Cre in *S1pr2*^+^ GC B cells ([Figure 2](#fig2){ref-type="fig"}F). We found that \>70%--80% of CD45.2 GC B cells expressed tdTomato, and HVEM surface expression was decreased to nearly *Hvem*^−/−^ levels in the GC but was unchanged in follicular B cells ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D). Importantly, *Hvem*^f/f^ *S1pr2*^ERT2Cre^ B cells were 30%--50% more represented in the GC than in the follicular compartment, whereas the control *Hvem*^f/f^ Cre^--^ and *Hvem*^+/+^ Cre^+^ GC B cells were equally represented ([Figure 2](#fig2){ref-type="fig"}G). A 1 hr EdU labeling analysis showed that a slightly greater fraction of HVEM-deficient than internal control GC B cells were proliferating ([Figure 2](#fig2){ref-type="fig"}H). As another way to test the impact of HVEM loss at the GC stage, we crossed *Hvem*-floxed animals to the *Cγ1*^Cre^ line, which acts earlier in the response and avoids the need for tamoxifen. In mixed BM chimeras, *Hvem*^f/f^*Cγ1*^Cre^ GC B cells had a growth advantage over the control GC B cells ([Figures S2](#mmc1){ref-type="supplementary-material"}E and S2F). These findings indicate that HVEM has a restraining influence on B cells during GC seeding and within the GC.

HVEM Signaling Intrinsic to the B Cell Is Not Required for GC B Cell Suppression {#sec2.4}
--------------------------------------------------------------------------------

To test whether HVEM signaling into the B cell is required for HVEM-mediated restraint of the GC response, we used a gain-of-function approach. BM-chimeric mice were generated with BM that had been transduced with MSCV-Thy1.1 retrovirus encoding full-length or mutated forms of *Hvem*, and the reconstituted mice were immunized with SRBCs ([Figures 3](#fig3){ref-type="fig"}A--3C). After overexpression of WT HVEM, Thy1.1 reporter^+^ GC B cells were 50% less represented than follicular B cells, whereas overexpression of an empty vector did not alter Thy1.1^+^ B cell participation in the GC ([Figures 3](#fig3){ref-type="fig"}C and 3D).Figure 3HVEM Signaling Intrinsic to the B Cell Is Not Required for GC B Cell Suppression(A) Experimental scheme and timeline for experiments in (B)--(G).(B) Model of HVEM WT, E271A (TRAF2/5 binding mutant), Δ235 (truncation of cytoplasmic tail), and Y61A (CRD1 binding mutant).(C) Representative flow-cytometric analysis of HVEM and Thy1.1 expression on Fo and GC B cells in BM chimeras transduced with empty vector (EV), HVEM WT, HVEM E271A, and HVEM Δ235.(D) Frequency of Thy1.1^+^ cells in GC versus Fo in *Hvem*^+/+^ BM-reconstituted chimeras. Data are pooled from three experiments.(E) Frequency of Thy1.1^+^ cells in GC versus Fo in *Hvem*^−/−^ BM-reconstituted chimeras. Data are pooled from two experiments.(F) Representative flow-cytometric analysis of HVEM and Thy1.1 expression on Fo and GC B cells in HVEM-Y61A-transduced BM chimeras.(G) Frequency of Thy1.1^+^ cells in GC versus Fo in *Hvem*^−/−^ BM in pLN response. Data are pooled from two experiments.Ordinary one-way ANOVA with Bonferroni's multiple-comparisons test (D, E, and G): ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001.

To determine whether loss of HVEM's ability to recruit TRAF2/5 affects GC B cell participation, we introduced a point mutation that is known to disrupt TRAF recruitment, E271A, into the HVEM cytoplasmic tail ([@bib24]). This mutant form of HVEM was expressed on the cell surface and repressed B cell participation in the GC to the same extent as WT HVEM ([Figures 3](#fig3){ref-type="fig"}B--3D). To rule out signaling via other parts of the HVEM cytoplasmic tail, we generated a mutant harboring a stop codon at position 235 (Δ235) immediately after the transmembrane domain. This construct suppressed B cell participation in the GC similarly to the WT ([Figures 3](#fig3){ref-type="fig"}B--3D). The Δ235 mutant also restrained B cell participation in the GC when expressed in *Hvem*^−/−^ cells ([Figure 3](#fig3){ref-type="fig"}E). These data demonstrate that HVEM's intrinsic signaling into the B cell is not required for its ability to restrain B cell participation in the GC response.

A point mutation at Y61A within the HVEM CRD1 disrupts binding to BTLA and CD160 ([@bib11]). Unlike WT HVEM, Y61A HVEM failed to reduce the participation of transduced B cells in the GC response, suggesting that HVEM's ability to bind a ligand through CRD1 is required ([Figures 3](#fig3){ref-type="fig"}F and 3G).

BTLA on CD4^+^ T Cells Is Required for HVEM-Deficient GC B Cell Competitiveness {#sec2.5}
-------------------------------------------------------------------------------

Given that BTLA is an inhibitory receptor highly expressed in the GC on both B cells and T cells ([Figure 4](#fig4){ref-type="fig"}A), we tested whether BTLA is required for HVEM's suppressive ability. When HVEM was overexpressed in *Btla*^−/−^ BM-chimeric mice, Thy1.1 reporter^+^ GC B cells participated in the GC at the same frequency as in follicular B cells ([Figure 4](#fig4){ref-type="fig"}B). This finding contrasts with the repressive effect of HVEM overexpression on B cells in WT BM-chimeric mice ([Figure 3](#fig3){ref-type="fig"}D) and suggests that BTLA is the relevant ligand for HVEM's ability to suppress participation in the GC.Figure 4BTLA on T Cells Restrains GC B Cell Competitiveness(A) Flow-cytometric analysis of BTLA expression on B cells (left) and CD4^+^ T cells (right) compared with *Btla*^−/−^ cells.(B) HVEM-overexpressing *Btla*^−/−^ BM chimeras were made by transduction of empty vector (EV) or HVEM (WT) MSCV-Thy1.1 constructs into *Btla*^−/−^ BM and reconstitution of CD4-depleted hosts. Chimeras were then immunized with SRBCs, and the participation of Thy1.1^+^ cells in GC versus Fo B cells was determined.(C) Contribution of *Btla*^+/+^ or *Btla*^−/−^ CD45.2 cells to Fo and GC populations in the spleen of mixed BM chimeras made with ∼40% CD45.2 and ∼60% WT CD45.1 at day 7 after SRBC immunization.(D) Experimental scheme and timeline for experiments in (E) and (F).(E) Ratio of the frequency of CD45.1/2 *Hvem*^−/−^ HEL^+^ B cells in BTLA-B-cell-deficient (*Btla*^f/f^*Mb1*^Cre^) hosts at day 5 to the pre-transfer frequency.(F) Ratio of CD45.1/2 *Hvem*^+/+^ or *Hvem*^−/−^ HEL^+^ GC B cells to the pre-transfer mix in BTLA-T-cell-deficient (*Btla*^f/f^*Cd4*^Cre^) hosts at days 3--6. Data are pooled from four experiments.Unpaired two-tailed Student's t test (B, C, E, and F): ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^\<P0.001, ^∗∗∗∗^p \< 0.0001. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

*In vitro* studies have shown that BTLA in B cells can inhibit BCR signaling, and it has been suggested that HVEM-BTLA can interact in *cis* within the same cell ([@bib11], [@bib60]), and a role for such *cis* interactions has been invoked to explain findings in a mouse FL model ([@bib4], [@bib25], [@bib61]). If the actions of HVEM in restraining B cell participation in the GC were dependent on *cis* engagement with BTLA, B cells lacking BTLA would be predicted to have a GC growth advantage similar to that observed for HVEM-deficient cells. Analysis of mice reconstituted with a mixture of WT and *Btla*^−/−^ BM showed that cell-intrinsic loss of BTLA did not alter the frequency of B cells in the GC ([Figure 4](#fig4){ref-type="fig"}C). Similar results were obtained when mixed BM chimeras were made with BM from *Btla*^f/f^ *Mb1*^Cre^ mice that selectively lack BTLA in B cells ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B).

To determine whether BTLA on bystander B cells acts in *trans* to influence antigen-reactive B cells, we transferred *Hvem*^−/−^ and WT Hy10 B cell mixes into *Btla*^f/f^ *Mb1*^Cre^ or control hosts that were then immunized with 2×-HEL-SRBC ([Figure 4](#fig4){ref-type="fig"}D). *Hvem*^−/−^ Hy10 B cells maintained their growth advantage in the BTLA-B-cell-deficient hosts, suggesting that bystander B cells are not the cellular source of BTLA for HVEM-mediated suppression of GC B cell participation ([Figure 4](#fig4){ref-type="fig"}E).

BTLA is a defining marker on Tfh cells compared with other CD4^+^ T cells ([Figure 4](#fig4){ref-type="fig"}A) ([@bib15], [@bib28], [@bib42]). To test whether HVEM-deficient GC B cell competitiveness requires BTLA-expressing T cells, we transferred *Hvem*^−/−^ and WT Hy10 B cell mixes into *Btla*^f/f^ *Cd4*^Cre^ hosts that lack BTLA in all T cells ([Figure S3](#mmc1){ref-type="supplementary-material"}A). The hosts were immunized with 2×-HEL-SRBC and analyzed at days 3--6 of the response ([Figure 4](#fig4){ref-type="fig"}D). The *Hvem*^−/−^ Hy10 GC B cell growth advantage was abrogated in BTLA-T-cell-deficient mice at all time points analyzed ([Figure 4](#fig4){ref-type="fig"}F and [Figure S3](#mmc1){ref-type="supplementary-material"}C). Tfh cells were present at similar frequencies in both types of recipient animals ([Figures S3](#mmc1){ref-type="supplementary-material"}D and S3E), and the frequency of HEL^+^ responding B cells was also similar ([Figure S3](#mmc1){ref-type="supplementary-material"}F). BTLA was upregulated in T cells between days 2 and 3 of the response ([Figures S3](#mmc1){ref-type="supplementary-material"}G and S3H), kinetics that matched the timing of when HVEM began to regulate the B cell proliferative response ([Figure 2](#fig2){ref-type="fig"}B). These data indicate that BTLA-expressing T cells are required for the *Hvem*^*−*/−^ GC B cell competitive advantage.

A previous study reported that BTLA deficiency led to increased IL-21 production by *in*-*vitro*-generated and -restimulated Tfh cells ([@bib28]). However, when Tfh cells were generated *in vivo*, we did not observe a difference in *Il21* expression between BTLA-deficient and WT Tfh cells from the same animals ([Figure S3](#mmc1){ref-type="supplementary-material"}I).

BTLA-HVEM at the Immunological Synapse Recruits SHP1 to Inhibit Signaling in Tfh Cells {#sec2.6}
--------------------------------------------------------------------------------------

To determine whether BTLA can alter CD4^+^ T cell signaling at the immunological synapse when it engages HVEM, we turned to the well-established supported lipid bilayer model ([@bib19]). Human CD4^+^ T cell blasts were transfected with BTLA to mimic the surface expression in Tfh cells ([Figure S4](#mmc1){ref-type="supplementary-material"}A) and settled on supported lipid bilayers containing anti-CD3 (UCHT1) and ICAM1 for 15 min before fixation. When HVEM was added to the bilayers, BTLA and HVEM were recruited to the synapse and formed a ring around the central synaptic cleft in cases where a stable synapse had been formed ([Figure 5](#fig5){ref-type="fig"}A). In the presence of HVEM, there was a shift in interface organization from the stable synapse to the motile kinapse state ([@bib38]), where the TCR cluster was at one pole of the interface ([Figure 5](#fig5){ref-type="fig"}B and [Figure S4](#mmc1){ref-type="supplementary-material"}B).Figure 5BTLA-HVEM at the Immunological Synapse Recruits SHP1 to Inhibit Signaling in Tfh Cells(A) Example total internal reflection fluorescence (TIRF) and interference reflection microscopy (IRM) images of BTLA-transfected human CD4^+^ T cell blasts on supported lipid bilayers containing anti-CD3, ICAM1, and where indicated, HVEM and/or CD80. Staining for CD3 (UCHT1), ICAM1, and BTLA is shown.(B) Quantification of kinapse versus synapse state of cells imaged as in (A).(C) Model of human BTLA binding mutant Y257F/Y282F, designed to disrupt SHP1 and SHP2 recruitment to the last two of four cytosolic tyrosines.(D) Representative images of SHP1 and SHP2 recruitment to the synapse in relation to that of WT or mutant BTLA.(E and F) Quantification of SHP1 (E) and SHP2 (F) colocalization with WT or mutant BTLA with or without HVEM in the bilayer as determined with Pearson's colocalization coefficient.(G) Representative images of pZAP70 in human Tfh cells in relation to HVEM in the bilayer after 15 min on the bilayer; a standardized lookup table (LUT) is shown across panels so fluorescence can be directly compared.(H) Relative amount of pZAP70 in BTLA-transfected CD4^+^ T cell blasts and Tfh cells with or without HVEM and CD80 in the bilayer (normalized to the condition without HVEM and CD80).(I) Representative images of pPKCθ in human Tfh cells in relation to HVEM in the bilayer after 15 min on the bilayer; a standardized LUT is shown across panels so fluorescence can be directly compared.(J) Relative amount of pPKCθ in BTLA-transfected CD4^+^ T cell blasts and Tfh cells with or without HVEM and CD80 in the bilayer (normalized to the condition without HVEM and CD80). Data are pooled from three independent donors and experiments.Scale bars: 5 μm. Chi-square and Fischer's exact tests (B) or Mann-Whitney test (E, F, H, and J): ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

BTLA has been shown to recruit SHP1 and SHP2 biochemically through Y257 and Y282 ([@bib22], [@bib65]). BTLA demonstrated strong colocalization with SHP1 at the synapse, whereas SHP2 did not preferentially co-localize ([Figures 5](#fig5){ref-type="fig"}C--5F). When the CD4^+^ T cells blasts were transfected with a BTLA Y257F/Y282F mutant, SHP1 colocalization was diminished and SHP2 was unchanged ([Figures 5](#fig5){ref-type="fig"}C--5F). The incomplete effect on SHP1 recruitment most likely reflects the activity of endogenous BTLA in the blasts. These results contrast with the PD-1 molecule that colocalizes preferentially with SHP2 at the synapse ([Figures S4](#mmc1){ref-type="supplementary-material"}C--S4F).

In accord with SHP1 recruitment, inclusion of HVEM in the bilayer inhibited the amount of signaling downstream of the TCR, as measured by pZAP70 and pPKCθ ([Figures 5](#fig5){ref-type="fig"}G--5J and [Figures S4](#mmc1){ref-type="supplementary-material"}G and S4H). This was observed for both BTLA-transfected CD4^+^ T cells and human tonsil-derived Tfh cells ([Figures 5](#fig5){ref-type="fig"}G--5J and [Figures S4](#mmc1){ref-type="supplementary-material"}G and S4H). Inclusion of the CD28 ligand CD80 in the bilayer led to an elevated amount of signaling, and HVEM continued to reduce, in most cases significantly, the extent of ZAP70 and PKCθ activation ([Figures 5](#fig5){ref-type="fig"}G--5J and [Figures S4](#mmc1){ref-type="supplementary-material"}G and S4H). These data suggest that HVEM engagement of BTLA inhibits T cell activation through SHP1 at the immunological synapse.

BTLA Signaling into the T Cell through SHP1 Is Required for HVEM-Deficient GC B Cell Competitiveness {#sec2.7}
----------------------------------------------------------------------------------------------------

To test whether BTLA signaling restrains the help provided to B cells, we generated a mutant mouse line (termed BTLA Y3) that lacks the BTLA cytoplasmic tail ([Figure 6](#fig6){ref-type="fig"}A and [Figure S5](#mmc1){ref-type="supplementary-material"}A). *Hvem*^−/−^ Hy10 spleen cell mixes were then transferred into *Btla*^+/+^, *Btla*^y3/y3^, and *Btla*^−/−^ hosts, and the mice were immunized with 2×-HEL-SRBC and analyzed at day 5. *Btla*^y3/y3^ hosts phenocopied *Btla*^−/−^ hosts by abrogating the *Hvem*^−/−^ Hy10 GC B cell competitive advantage ([Figure 6](#fig6){ref-type="fig"}B). BTLA Y3 mutant protein was less expressed on the T cell surface than on WT Tfh cells ([Figure S5](#mmc1){ref-type="supplementary-material"}B). To control for possible effects of the reduced expression, we also performed transfers into *Btla*^+/−^ recipients whose T cell BTLA expression was similar to that of *Btla^y3/y3^* mice ([Figure S5](#mmc1){ref-type="supplementary-material"}B). The *Hvem*^−/−^ B cells showed a similar competitive advantage in BTLA heterozygous and WT hosts ([Figure 6](#fig6){ref-type="fig"}B). These findings provide evidence that the BTLA cytoplasmic domain in host T cells is required for HVEM-mediated restraint of B cell participation in the GC response.Figure 6BTLA Signaling into the T Cell through SHP1 Is Required for HVEM-Deficient GC B Cell Competitiveness(A) Model of murine BTLA truncation, termed Y3, in which all three cytoplasmic tyrosines have been removed.(B) Ratio of *Hvem*^−/−^ GFP^+^HEL^+^ GC (IgD^lo^Fas^+^) B cells to the pre-transfer mix (∼20% *Hvem*^−/−^ GFP^+^ Hy10 to ∼80% WT CD45.1 Hy10) in *Btla*^+/+^, *Btla*^+/−^, *Btla*^y3/y3^, and *Btla*^−/−^ hosts. Data are pooled from two experiments.(C) Ratio of *Hvem*^+/+^ or *Hvem*^−/−^ GFP^+^HEL^+^ GC B cells to the pre-transfer mix in *Ptpn6*^f/f^ (SHP1) *Cd4*^Cre^ or control hosts. Data are pooled from four experiments.(D) Ratio of *Hvem*^+/+^ or *Hvem*^−/−^ GFP^+^HEL^+^ GC B cells to the pre-transfer mix in *Ptpn11*^f/f^ (SHP2) *Cd4*^Cre^ or control hosts. Data are pooled from three experiments.(E) Representative flow-cytometric analysis of CD40L surface mobilization on OT-II Tfh cells after a 30 min of incubation; B cells were pulsed with a titration of OVA peptide (0--10 μM).(F) CD40L expression on OT-II Tfh cells stimulated as in (E) (normalized to expression on unstimulated Tfh cells). Data are pooled from three experiments.(G) Representative flow-cytometric analysis of CD40L surface mobilization on OT-II Tfh cells after 60 min of stimulation on OVA-peptide-pulsed *Hvem*^+/+^ or *Hvem*^−/−^ B cells.(H) Normalized CD40L mean fluorescence intensity on OT-II Tfh cells 30 or 60 min after stimulation with OVA-loaded *Hvem*^+/+^ or *Hvem*^−/−^ B cells (2 or 10 μM). Data are pooled from two experiments.(I) Representative images of CD40 recruitment to the immunological synapse with or without HVEM and CD80 present in the lipid bilayer after 15 min of incubation with human Tfh cells; a standardized LUT is shown across panels so fluorescence can be directly compared. Upper images show immunofluorescence (IF), middle images show overlayed IF and IRM, and lower images show IRM.(J) Relative CD40 accumulation at synaptic interface in BTLA-transfected CD4^+^ T cell blasts and Tfh cells with or without HVEM and CD80 in the bilayer (normalized to the condition without HVEM and CD80). Data are pooled from three independent donors and experiments.Scale bars: 5 μm. Ordinary one-way ANOVA with Bonferroni's multiple-comparisons test (B--D), unpaired two-tailed Student's test (F), paired two-tailed Student's test (H), or Mann-Whitney test (J): ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

To test which of BTLA's intracellular binding partners in the T cell restrains the signal to HVEM-expressing GC B cells, we transferred *Hvem*^−/−^ and WT Hy10 B cell mixes into *Ptpn6*^fl/fl^ (SHP1) and *Ptpn11*^fl/fl^ (SHP2) *Cd4*^Cre^ or control hosts. Splenic Tfh cell frequencies in the SHP1 and SHP2 T-cell-deficient hosts were similar to those in controls ([Figures S5](#mmc1){ref-type="supplementary-material"}C and S5D). The *Hvem*^−/−^ GC B cell competitive advantage was lost in SHP1 T-cell-deficient hosts, whereas it was maintained in SHP2 T-cell-deficient hosts ([Figures 6](#fig6){ref-type="fig"}C and 6D). The frequency of HEL-binding B cells in both host types was comparable to that in controls ([Figures S5](#mmc1){ref-type="supplementary-material"}E and S5F). These data suggest that after HVEM engagement, BTLA recruits SHP1 to moderate the activation of the T cell and the amount of help provided to the HVEM-expressing B cell.

HVEM-BTLA Interaction Reduces the Amount of CD40-CD40L Brought to the Synaptic Interface {#sec2.8}
----------------------------------------------------------------------------------------

For a Tfh cell to provide greater help to HVEM-deficient B cells than to HVEM-expressing B cells in the same GC microenvironment during interactions that often last only a few minutes, Tfh cell BTLA most likely has to regulate the mobilization of a preformed mediator. The best defined pre-formed helper factor in Tfh cells is CD40L ([@bib8], [@bib29], [@bib30]). However, it has been unclear whether the amount of preformed CD40L displayed on the T cell surface can be tuned by the strength of the TCR signal. As one approach to test this, we incubated OVA-specific OT-II Tfh cells for 30 min with B cells that had been pulsed with a range of OVA-peptide concentrations. A 30 min incubation was chosen as a time that allowed cells to interact in the *in vitro* environment while being sufficiently short to ensure that only preformed CD40L could be mobilized. Although the B cells were not intentionally activated, they expressed ICOSL ([@bib67]) and upregulated CD86 during the incubation ([Figure S5](#mmc1){ref-type="supplementary-material"}G), properties that could contribute to their ability to activate Tfh cells. Compared with unstimulated Tfh cell expression of CD40L, B cells presenting increasing amounts of OVA peptide led to an analog upregulation of CD40L on the Tfh cell surface by 30 min, and this was further increased after 60 min ([Figures 6](#fig6){ref-type="fig"}E and 6F and [Figures S5](#mmc1){ref-type="supplementary-material"}H and S5I).

We next tested whether HVEM deficiency on OVA-peptide-pulsed B cells influences CD40L upregulation on Tfh cells. Analysis at 30 and 60 min revealed that CD40L exposure was slightly but significantly higher on Tfh cells interacting with HVEM-deficient B cells than on Tfh cells interacting with WT B cells ([Figures 6](#fig6){ref-type="fig"}G and 6H). Past studies have shown that CD40 is recruited to the immune synapse in a CD40L-dependent manner ([@bib5], [@bib46]). We therefore returned to the supported lipid bilayer as another approach to test the ability of BTLA to regulate preformed CD40L upregulation. Human CD4^+^ T cell blasts and human Tfh cells were plated on the bilayer containing anti-CD3, ICAM1, CD40, and in some cases CD80. When HVEM was added to the bilayer, the amount of CD40 recruited to the synapse in the 15 min assay was reduced in both the blasts and the Tfh cells ([Figures 6](#fig6){ref-type="fig"}I and 6J and [Figure S5](#mmc1){ref-type="supplementary-material"}J). These data suggest that BTLA can restrain the amount of preformed CD40L that is mobilized to the immunological synapse and thus the quality of T cell help.

To examine whether increased T cell help could be read out in the *Hvem*^−/−^ GC B cell as a transcriptional change, we performed RNA sequencing on GC B cells from mixed BM chimeras. The top differentially expressed genes in *Hvem*^−/−^ GC B cells compared with WT GC B cells corresponded to Gene Ontology biological processes for positive regulation of cell-cycle progression ([Figure S5](#mmc1){ref-type="supplementary-material"}K). Previous studies have shown that Tfh cell help signals through CD40 to activate Myc and mTOR1 signaling in GC B cells ([@bib7], [@bib18], [@bib20], [@bib36]). Gene-set enrichment analysis (GSEA) revealed that *Hvem*^−/−^ GC B cells had more Myc gene signatures than their WT competitors ([Figure S5](#mmc1){ref-type="supplementary-material"}L) ([@bib72]). *Hvem*^−/−^ GC B cells were also enriched with a set of rapamycin-sensitive genes induced downstream of T cell help in GC B cells ([Figure S5](#mmc1){ref-type="supplementary-material"}M) ([@bib20]). These data suggest that *Hvem*^−/−^ B cells receive more T helper signals than their WT competitors.

BTLA Deficiency in T Cells Leads to GC B Cell Expansion in the Setting of Bcl-2 Overexpression {#sec2.9}
----------------------------------------------------------------------------------------------

*HVEM* mutations in human GC-derived lymphomas often occur in the setting of Bcl-2 overexpression. To determine whether the HVEM-deficient GC growth advantage occurs when B cells constitutively express Bcl-2, we generated *Hvem*^−/−^ *BCL2*-tg mice. Irradiated recipient mice were reconstituted with a mixture of CD45.2 *Hvem*^−/−^ *BCL2*-tg BM and congenically distinguished WT *BCL2*-tg BM, and the chimeric animals were immunized with SRBCs. The HVEM-deficient Bcl-2 GC B cells maintained their growth advantage over WT Bcl-2 competitors ([Figure 7](#fig7){ref-type="fig"}A). These data indicate that the growth-promoting pathway mediated by HVEM deficiency is distinct from the pro-survival pathway mediated by Bcl-2.Figure 7BTLA Deficiency in T Cells Leads to GC B Cell Expansion in the Setting of Bcl-2 Overexpression(A) Frequency of CD45.2 splenic Fo and GC B cells of Bcl-2 transgenic origin in mixed BM chimeras reconstituted with 30%--50% *Hvem*^+/+^, *Hvem*^+/−^, or *Hvem*^−/−^ Eμ-BCL2-tg CD45.2 BM and 50%--70% WT Eμ-BCL2-tg CD45.1/2 BM at day 7 after SRBC immunization. Data are pooled from three experiments.(B and C) The frequency (B) and number (C) of spontaneously forming splenic GC B cells in mice reconstituted for 6--14 weeks with *Hvem*^+/+^or *Hvem*^−/−^ BM transduced with MSCV-Bcl2-Thy1.1. Data are pooled from two experiments.(D) Representative flow-cytometric analysis of spontaneous GC formation in the spleen after 8 weeks of reconstitution with *Btla*^f/f^ or *Btla*^f/f^*Cd4*^Cre^ BM transduced with MSCV-Bcl2-Thy1.1. Irradiated *Rag2*^−/−^ or *Tcrb*^−/−^ mice were used as hosts.(E and F) The frequency (E) and number (F) of spontaneously forming splenic GC B cells in BM chimeras from (D). Data are pooled from three experiments.(G) V~H~- and V~L~-region PCR analysis of GC B cells from two *Btla*^f/f^*Cd4*^Cre^ chimeras with splenic GC outgrowths \> 20% and two *Btla*^f/f^ control chimeras.Unpaired two-tailed Student's test (B,C, E, and F): ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗∗^p \< 0.0001.

Bcl-2 is very highly expressed in human FL, and previous work has shown that lines of mice expressing higher amounts of Bcl-2 in B cells than the *BCL2*-tg line have a higher propensity to form lymphomas ([@bib43]). To generate mice with higher expression of Bcl-2 in B cells, we transduced WT or *Hvem*^−/−^ BM with a MSCV-*Bcl2*-Thy1.1 construct. After we reconstituted WT hosts, the Bcl-2-overexpressing BM chimeras generated large splenic GCs in unimmunized mice as early as week 6 after reconstitution, and the GCs increased in size through 14 weeks ([Figures 7](#fig7){ref-type="fig"}B and 7C). Compared with WT chimeras, *Hvem*^−/−^ chimeras had increased GC B cell expansion, suggesting that HVEM deficiency cooperates with strong Bcl-2 overexpression.

On the basis of our findings in the preceding sections, we hypothesized that BTLA in the T cell could restrain the amount of help provided to the GC B cell in the setting of Bcl-2 overexpression. To test this possibility, we transduced *Btla*^f/f^ *Cd4*^Cre^ or control BM with the MSCV-*Bcl2*-Thy1.1 construct and used it to reconstitute *Rag2*^−/−^ or *Tcrb*^−/−^ mice. We used T-cell-deficient mice as hosts to ensure an absence of radioresistant WT T cells. When Bcl-2-overexpressing B cells developed in an environment where all the T cells were BTLA deficient, there was increased GC B cell expansion in the spleen ([Figures 7](#fig7){ref-type="fig"}D--7F). VH- and VL-region PCR analysis of GC B cells from two of the *Btla*^f/f^ *Cd4*^Cre^ BM chimeras with GC B cell frequencies exceeding 20% of splenic B cells showed evidence of clonal outgrowths ([Figure 7](#fig7){ref-type="fig"}G). Clonal dominance was not observable for the light chain, perhaps because even small numbers of polyclonal cells prevent an abundant clone from dominating this PCR reaction. All together, these data indicate that BTLA on the T cell acts as a cell-extrinsic suppressor of Bcl-2-overexpressing GC B cell expansion.

Discussion {#sec3}
==========

The above findings establish that engagement of BTLA on helper T cells by HVEM on B cells signals to restrain B cell expansion during the generation of GC cells and PBs and also acts as a restraint on B cells within the GC. The negative signaling into the T cell depends on the BTLA cytoplasmic domain and on SHP1 recruitment. HVEM engagement of BTLA reduces proximal TCR signaling, and this reduces the output of CD40L and most likely other preformed mediators from the T cell. HVEM thereby restrains B cell proliferation, differentiation, and selection by reducing the delivery of helper signals from the T cell. We also found that the T helper signals restrained by the HVEM-BTLA interaction can exert their growth-promoting effects on Bcl-2-overexpressing (pre-malignant) B cells, providing evidence that BTLA might act as a cell-extrinsic repressor of B cell lymphomagenesis.

Under competitive conditions, proliferation of HVEM-deficient B cells was favored over that of WT B cells, in agreement with other models of B cell competition for T cell help ([@bib23], [@bib52], [@bib73], [@bib20], [@bib69]). When C57BL/6 mice were deficient in HVEM in all B cells or deficient in BTLA in all T cells, although there was a trend toward increased GC frequencies, the GC response was not significantly enlarged. A study in BALB/c mice reported an enlarged GC response when BTLA was absent, suggesting that the extent of BTLA-mediated regulation of GC B cells might be influenced by background genes ([@bib28]). Although we observed a slight increase in *Hvem*^−/−^ GC B cell proliferation in mixed settings across several time points, we did not observe a progressive increase in *Hvem*^−/−^ B cell representation within the GC over time, suggesting there should be increased output of *Hvem*^−/−^ cells from the GC to account for the extra cells generated by proliferation. Our inability to detect more GC B cell death or more Bmem or PC representation than B cell representation in the GC could be because of a small effect size and the possibility that more than one of these output parameters is affected. In addition to leading to increased proliferation of HVEM-deficient cells, lack of HVEM on some B cells appeared to reduce proliferation of competing WT B cells in the same animal. The exact mechanism of the diminished response of the WT cells is unclear, but one possibility is that Tfh cells harbor a limited amount of preformed helper factors (such as CD40L), and when greater amounts are delivered to some cells (*Hvem*^−/−^ in this case), less is available for the other cells present in the same microenvironment. A related possibility, suggested by the propensity of HVEM to convert stable synapses to motile kinapses, is that the increased stability of *Hvem*^−/−^ B cell interactions with Tfh cells diminishes the contact of WT B cells with Tfh cells.

B-T interactions generally occur over periods of minutes, making it unlikely that there is sufficient time for B-cell-triggered induction of new transcription to affect the T cell help delivered during a given contact. Although previous studies have shown that CD40L can be upregulated in a graded manner in proportion to the amount of TCR engagement, these studies were done over periods of 16--20 hr and most likely involved transcriptional induction ([@bib27], [@bib50]). In our study, we found that the rapid display of preformed CD40L on Tfh cells occurred in a manner proportional to the amount of MHC peptide on the B cells. In accordance with the fact that stronger signaling into the T cell mobilizes more preformed CD40L, previous work found that co-engagement of ICOS and the TCR enhances CD40L externalization ([@bib35], [@bib46]). These combined observations suggest that the BTLA-mediated restraint of TCR-induced CD40L mobilization in T cells is due to the negative regulation of proximal TCR signaling.

In biochemical studies, BTLA co-immunoprecipitates with SHP1 and SHP2 ([@bib22], [@bib65]). The molecular basis for the preferential coupling to SHP1 observed here in Tfh cells is not yet known and will need further investigation. These observations contrast with findings for PD-1, which preferentially associates with SHP2 in immune synapse studies with CD4^+^ and CD8^+^ T cells ([@bib26], [@bib71]; this study). However, an *in vivo* study suggests that PD-1 function in effector CD8 T cells is not fully dependent on SHP2 ([@bib49]). Given that PD-1 and BTLA are both highly expressed on Tfh cells, it will be important to determine whether PD-1 in Tfh cells *in vivo* depends on SHP2 because this could indicate qualitative differences in the type of regulation exerted in Tfh cells by these related checkpoint-family proteins.

HVEM-mediated restraint of the B cell response did not begin immediately, suggesting that some temporal event needs to take place before HVEM-BTLA signaling becomes influential. We speculate that this could at least in part reflect the need for Bcl6 and BTLA upregulation in the activated T cell given that the influence of HVEM deficiency was lost in mice lacking Bcl6 in T cells. It is notable that HVEM surface levels are lower on both mouse and human GC B cells than on naive and early activated B cells. Given the strong growth-repressive effects observed in HVEM gain-of-function experiments, the reduced HVEM levels could be important in permitting transmission of the helper signals needed to support the strong proliferative responses of GC B cells.

Predicting the impact of greater T cell help (indiscriminate of the amount of MHC peptide presented) on the repertoire of B cells selected in the GC is not straightforward. We found that selection of NP-binding B cells was disfavored in HVEM-deficient B cells, perhaps indicating an increased competitiveness of carrier-specific B cells that would normally receive inadequate T cell help and be outcompeted by B cells responding to the readily accessible and highly multivalent NP hapten. Our inability to detect a differential effect of HVEM deficiency on the proliferative response of Hy10 B cells responding to DEL (K~A~ 10^7^ M^−1^) versus HEL (K~A~ 10^10^ M^−1^) ([@bib34]) could be because both antigens are in the high-affinity range, and the oligomeric state of the OVA conjugates could further diminish differences in antigen capture and MHC peptide presentation. In the context of NP-based immunizations, a similar increase in representation of non-NP binding B cells has been seen in immunized PD-L1-deficient mice ([@bib55]). The fraction of cells harboring the affinity-improving W33L mutation was lower within the NP-binding *Hvem*^−/−^ GC B cell population than in the internal control WT cell population. It was notable that W33L mutations were more frequent in the WT cells competing with *Hvem*^−/−^ cells than in those competing with other WT cells. One interpretation of these findings is that by diminishing the helper signals available to WT B cells, the HVEM-deficient B cells promote stronger selection for those WT B cells that are able to present the highest amounts of antigen. The combined observations suggest that negative costimulatory molecule signaling in Tfh cells is necessary to maintain the stringency of GC selection. A reduction in B cell selection stringency could explain the autoantibody production that occurs in aged BTLA-deficient 129/SvEV mice ([@bib45])

In agreement with a previous study on Bcl-2-overexpressing BM chimeras ([@bib4]), in which *Hvem* shRNA-targeted B cells preferentially contributed to GC-derived lymphomas, we found that B cell HVEM deficiency cooperated with Bcl-2 overexpression in promoting GC outgrowth. The authors of the previous study also found that shRNA targeting of *Btla* in hematopoietic cells (HSCs) led to GC lymphomas and attributed this to a mechanism whereby *cis* engagement of BTLA by HVEM leads to BTLA-mediated downregulation of tumor-promoting BCR signals ([@bib4], [@bib25], [@bib61]). In the experiments here, we did not observe any evidence for *cis* or *trans* effects of deleting BTLA from B cells, as measured by participation in the GC response. Instead, we found that deletion of BTLA from T cells led to a growth advantage for HVEM-expressing B cells, including in the setting of Bcl-2 overexpression. Although an important distinction between these studies is that we measured GC participation and Boice et al. measured B cell lymphomagenesis, we believe that the different conclusions can be reconciled. Specifically, Boice et al. did not report enrichment of shRNA-*Btla* B cells over control B cells in BM chimeras, making it seem unlikely that *cis* HVEM-BTLA interaction could be the principle mechanism of HVEM-mediated tumor suppression. Although they also proposed *trans* engagement by HVEM expressed in other B cells ([@bib4]), we believe a more likely explanation for the lymphomas arising in some of the chimeras with shRNA-*Btla* HSCs is that *Btla* transcripts are reduced in the Tfh cell compartment. We believe that our findings together with Boice et al.'s shRNA chimera data support a revised model in which *HVEM* mutation in B cells leads to a loss of negative signaling in Tfh cells and allows *HVEM*-mutant B cells to receive exaggerated helper signals that promote proliferation and accrual of activation-induced cytidine deaminase (AID)-mediated mutations. In this regard, it is notable that FL is known for its rich presence of Tfh cells ([@bib17], [@bib25], [@bib61]). Importantly, the therapeutic benefit of elevating HVEM levels in the FL setting, as [@bib4] achieved, by using CAR T cells might act by diminishing Tfh cell function and thus support FL cell growth. Future studies are needed to test whether soluble HVEM can reduce Tfh cell function during GC responses and in lymphoma models where B cell HVEM has been mutated.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**B220 APC-CY7 (clone RA3-6B2)BD Bioscience\#552094; RRID: [AB_394335](nif-antibody:AB_394335){#interref0070}B220 BV785 (clone RA3-6B2)BioLegend\#103246IgD FITC (clone 11-26c.2a)BioLegend\#405704; RRID: [AB_394859](nif-antibody:AB_394859){#interref0075}GL-7 Pacific Blue (clone GL7)BioLegend\#144614FAS PE-CY7 (clone Jo2)BD Bioscience\#557653CD38 AlexaFluor647 (clone 90)BioLegend\#102718CD45.1 PERCP-CY5.5, APC (clone A20)Tonbo\#65-0453-U100CD45.2 BV605 (clone 104)BioLegend\#109841CD45.2 APC-CY7 (clone 104)BioLegend\#109824; RRID: [AB_1727492](nif-antibody:AB_1727492){#interref0080}HVEM PE (clone LH1)eBioscience\#12-5962-80; RRID: [AB_953628](nif-antibody:AB_953628){#interref0085}BTLA AlexaFluor 647 (8F4)BioLegend\#134808Ephrin-B1 Biotin (polyclonal, R&D)R&D\#BAF473CXCR4 Biotin (clone 2B11/CXCR4)BD Bioscience\#551968CD86 AlexaFluor647 (clone GL-1)BioLegend\#105020IgG1 FITC (clone RMG1-1)BioLegend\#406606CD138 BV421 (clone 281-2)BioLegend\#142508CD73 PERCP-CY5.5 (clone TY/11.8)BioLegend\#127214CD4 PE-CY7 (clone GK1.5)BD Bioscience\#552775TCRβ Pacific Blue (clone H57-597)BioLegend\#109226CXCR5 BV605 (clone L138D7)BioLegend\#145513PD-1 PE (clone 29F.1A12)BioLegend\#135206PD-1 FITC (clone 29F.1A12)BioLegend\#135214CD40L PE (clone MR1)BioLegend\#106506; RRID: [AB_313270](nif-antibody:AB_313270){#interref0090}Vα2 PERCP-CY5.5 (clone B20.1)BD Bioscience\#560529Fixable viability dye eFluor780 (eBioscience)eBioscience\#65-0865-18NP-47-PE (Biosearch technologies)Biosearch Technologies\#N-5070-1Active caspase-3 (clone C92-605)BD Bioscience\#559565BTLA AlexaFluor 647 (clone MIH26)BioLegend\#344520CXCR5 AlexaFluor 488 (clone RF8B2)BD Bioscience\#558112CXCR5 PE/Cy7 (clone J252D4)BioLegend\#356923PD1 AlexaFluor 488 (clone EH12.2H7)BioLegend\#329935PD1 AlexaFluor 647 (clone EH12.2H7)BioLegend\#329910CD19 PE/Cy7 (clone SJ25C1)BD Bioscience\#560911CD38 AlexaFluor 488 (clone HIT2)BioLegend\#303511CD27 BrilliantViolet421 (clone M-T271)BioLegend\#356417CD20 PE (clone 2H7)BioLegend\#302305HVEM AlexaFluor 647 (clone 94801)BD Bioscience\#564411SHP1 (clone C-19)Santa Cruz Biotechnology\#sc-287SHP2 (clone C-18)Santa Cruz Biotechnology\#sc-280; RRID: [AB_632401](nif-antibody:AB_632401){#interref0095}pT538 PKCθ (polyclonal)Cell Signaling Technology\#9377pY493 ZAP70 (polyclonal)Cell Signaling Technology\#2704Goat anti-rabbit F(ab')2 AlexaFluor 568 (polyclonal)Thermo Fisher Scientific\#A-21069Anti-CD3 monobiotinylated (clone OKT3)eBioscience\#13-0037-82**Bacterial and Virus Strains**5-alpha F'Iq Competent *E. coli* (High Efficiency)New England Bioscience\#C2992H**Biological Samples**Healthy adult blood -- leukocyte conesUK NHS Blood and Transplant<https://www.nhsbt.nhs.uk/>Adult tonsillectomy tissue -- whole tonsilsUK NHS Blood and Transplant<https://www.nhsbt.nhs.uk/>**Chemicals, Peptides, and Recombinant Proteins**4-Hydroxy-3-nitrophenylacetyl (NP)-20-29-Chicken gamma globulin (CGG)Biosearch Technologies\#N-5055C-5Alhydrogel aluminum hydroxide (alum) gel 6.5 mg/mLAccurate Chemical & Scientific Corporation\#A1090SOVA peptide (323-339)GenScript\#RP10610Human IL-2Peprotech\#200-021,2-dioleoyl-sn-glycero-3-phosphocholineAvanti Polar Lipids\#860377P1,2-dioleoyl-sn-glycero-3-\[(N-(5-amino-1-carboxypentyl) iminodiacetic acid) succinyl\]-NiAvanti Polar Lipids\#790404PHuman HVEM-Fc-HisSimon Davis LaboratoryN/AHuman ICAM1-HisMichael Dustin LaboratoryN/AHuman CD40-HisMichael Dustin LaboratoryN/AHuman CD80-HisMichael Dustin LaboratoryN/AAnti-Human CD3 FaB-His (clone UCHT1)Michael Dustin LaboratoryN/ASNAP-Cell 647-SiR ligandNew England Biolabs\#S9102Human CD58-HisMichael Dustin LaboratoryN/AHuman PDL1-HisMichael Dustin LaboratoryN/A**Critical Commercial Assays**Click-iT Plus EdU Alexa Fluor 647 Flow Cytometry Assay Kit 100 TestsInvitrogen\#C10635RosetteSep Human CD4+ T Cell Enrichment CocktailStemCell Technologies\#15062Anti-Human CD3/CD28 DynabeadsGIBCO\#111.32DmMESSAGE mMACHINE T7 ULTRA Transcription KitThermo Fisher Scientific\#AM1345EasySep CD4+ Isolation KitStemCell Technologies\#17952**Deposited Data**RNA sequencing dataThis paperGEO: [GSE130095](ncbi-geo:GSE130095){#intref0020}**Experimental Models: Cell Lines**Platinum-E (Plat-E) Retroviral Packaging Cell LineGift from S. SchwabN/A**Experimental Models: Organisms/Strains**Mouse: B6-CD45.1 Strain ID: B6.SJL-*Ptprc*^a^*Pepc*^b^*/*BoyCrCrlNCI at Charles RiverStock No: 564Mouse: *Hvem* flox Strain ID: B6;SJL-*Tnfrsf14*^*tm1.1Kro*^/JJackson LaboratoriesStock No: 030862Mouse: *Hvem*^−/−^ derived from *Hvem* flox[@bib54]N/AMouse: *Hvem14*^−/−^[@bib63]N/AMouse: *Btla* floxThis paperN/AMouse: *Btla*^−/−^ Strain ID: B6.129-*Btla*^*tm1Kmm*^/JJackson LaboratoriesStock No: 008336Mouse: *Ptpn6* flox Strain ID: B6.129P2-*Ptpn6*^*tm1Rsky*^/JJackson LaboratoriesStock No.: 008336Mouse: *Ptpn11* flox Strain ID: *Ptpn11*^*tm1.1Wbm*^/JJackson LaboratoriesStock No.: 025758Mouse: *Bcl6* flox Strain ID: B6.129S(FVB)-*Bcl6*^*tm1.1Dent*^/JJackson LaboratoriesStock No.: 023727Mouse: *Cγ1*-Cre Strain ID: B6.129P2(Cg)-*Ighg1*^*tm1(cre)Cgn*^/JJackson LaboratoriesStock No.: 010611Mouse: *S1pr2*-ERT2Cre tdTomato Flox[@bib56]N/AMouse: *Mb1*-Cre Strain ID: B6.C(Cg)-*Cd79a*^*tm1(cre)Reth*^/EhobJJackson LaboratoriesStock No.: 020505Mouse: *Cd4*-Cre Strain ID: B6.Cg-Tg(Cd4-cre)1Cwi/BfluJJackson LaboratoriesStock No.: 022071Mouse: Hy10 (VDJ9/K5)[@bib1]N/AMouse: OT-II Strain ID: Tg(TcraTcrb)426-6CbnMGI [4836972](mgi:4836972){#intref0025}N/AMouse: *Rag2*-deficient Strain ID: B6(Cg)-*Rag2*^*tm1.1Cgn*^/JJackson Laboratories008449Mouse: Eμ-*BCL2*-tg Strain ID: B6.Cg-Tg(BCL2)22Wehi/JJackson Laboratories002319Mouse: *Tcrb*^−/−^ Strain ID: B6.129P2-*Tcrb*^*tm1Mom*^/JJackson Laboratories002118Mouse: *Btla-*Y3This paperThis paper**Oligonucleotides***Hvem* (*Tnfrsf14*) qPCR primers: GGAGCTGGGATAGCT\
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Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jason G. Cyster (<jason.cyster@ucsf.edu>). The mouse lines obtained from other laboratories are described below and may require a Material Transfer Agreement (MTA) with the providing scientists. BTLAY3 mice generated in this study are available from our laboratory, also with an MTA.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Mice {#sec4.3.1}

Adult C57BL6 CD45.1 mice at least 7 weeks of age were from the National Cancer Institute. *Hvem* flox animals (JAX stock 030862) and *Hvem*-deficient animals ([@bib54]) were used in most studies. In one experiment mixed chimeras were generated from a separate *Hvem*-deficient line ([@bib63]). *Btla* flox animals have loxp sites flanking exons 4 and 5 of *Btla* gene (J.-W.S. and M.K., unpublished data). Full *Btla* deficient mice were from JAX stock 006353 ([@bib65]). Other lines included *Ptpn6* flox (JAX stock 008336), *Ptpn11* flox (JAX stock 025758), *Bcl6* flox (JAX 023727), *Cγ1*-Cre (JAX stock 010611), *S1pr2-*ERT2Cre tdTomato Flox ([@bib56]), *Mb1*-Cre (JAX stock 020505), *Cd4*-Cre (JAX stock 022071), Hy10 ([@bib1]), OT-II (MGI [4836972](mgi:4836972){#intref0055}), and *Rag2*^−/−^ (JAX stock 008449), *Tcrb*^−/−^ (JAX stock 002118), Eμ-BCL2-tg (JAX stock 002319), and *Btla*-y3/y3 animals were generated and maintained in our laboratory. In most experiments, littermates were used as controls and experimental animals were co-caged in groups of 2--6 whenever possible. Male and female mice were used as both donors and recipients, except for OT-II animals, which required male donors. Animals were housed in specific pathogen free environment in the Laboratory Animal Research Center at UCSF and all experiments conformed to ethical principles and guidelines approved by the UCSF Institutional Animal Care and Use Committee.

Method Details {#sec4.4}
--------------

### Generation of BTLAY3 Mice {#sec4.4.1}

*Btla*-y3/y3 animals were generated using crRNA1:TCATAAATTCCAGTTCCTGA targeting guide. The protocol followed Chen et al. ([@bib10]) with the main exception that the standard square curve electroporation was performed twice with an interval of 3 s. RNP assembly followed standard protocol: 160 μM tracrRNA + 160 μM crRNA (Dharmacon), equal volume mix well 37°C, 30 min (80 μM sgRNA); 80 μM sgRNA + 40 μM Cas9 Protein equal volume mix well 37°C 10 min (20 μM RNPs); leave on ice, each electroporation 10 μL of RNPs mix with 10 μL Opti-MEM with C57B6/J embryos. Standard electroporation: two pulses 30V for 3 ms interval 100 ms. Embryos were transferred into pseudo-pregnant females.

### Bone Marrow Chimeras {#sec4.4.2}

WT CD45.1, or *Rag2*^−/−^, or *Tcrb*^−/−^ where indicated, were lethally irradiated with 1,100 rads gamma-irradiation (split dose separated by 3 h) and then i.v. injected with relevant BM cells. BM was harvested by flushing the tibia and femurs. For T cell depletion (when necessary), 250 μg of anti-CD4 GK1.5 (BioXcell) was injected i.v. at day −1 and day 0.

### Retroviral Constructs and Transductions {#sec4.4.3}

Murine HVEM and Bcl2 retroviral constructs were made by inserting the mouse open reading frame into the MSCV2.2 retroviral vector followed by an internal ribosome entry site (IRES) and Thy1.1 as an expression marker. *Hvem* point mutations were introduced by quick-change PCR and *Hvem* truncation was introduced by PCR. Retrovirus was generated by transfecting PLAT-E packaging cell line with 10 μg plasmid DNA and 10 μg Lipofectamine 2000 (Fischer). For transduction of BM, WT, *Hvem*^−/−^, or *Btla*^−/−^ mice were injected i.v. with 3 mg 5-fluorouracil (Sigma). BM was collected after 4 days and cultured in DMEM containing 15% (vol/vol) FBS, antibiotics (penicillin (50 IU/mL) and streptomycin (50 μg/mL); Cellgro) and 10 mM HEPES, pH 7.2 (Cellgro), supplemented with IL-3, IL-6 and stem cell factor (at concentrations of 20, 50 and 100 ng/mL, respectively; Peprotech). Cells were 'spin-infected' twice at days 1 and 2 and were transferred into irradiated recipients on day 3.

### Cell Isolation and Adoptive Transfer {#sec4.4.4}

Spleens were macerated and resulting cell suspensions were filtered through a 70 μm mesh into PBS supplemented with 2% FCS and 1mM EDTA. Cells were counted on a hemocytometer and frequency of HEL^+^ Hy10 B cell was determined by staining of HEL-AlexaFluor647 (made using Invitrogen Alexa Fluor 647 antibody labeling kit) positive B cells on the flow cytometer. Mixes of *Hvem*^−/−^ or *Hvem*^+/+^ Hy10 and WT Hy10 congenically mismatched B cells were made at ratios of 1:4-1:1 as indicated in the figures. In some experiments OT-II T cells were co-transferred at a ratio of 1:5 Hy10 B cell as indicated in the figures. Mixtures of 5 × 10^4^ - 2 × 10^5^ cells were transferred i.v. in a volume of 200 μL into the retro-orbital venous sinus. To visualize cell proliferation, cells were labeled with Cell Trace Violet (CTV) (Invitrogen).

### Immunizations {#sec4.4.5}

Hosts were immunized with an intermediate affinity mutant 2x-HEL ([@bib47]) (Gift of R. Brink) conjugated to SRBC (Colorado Serum Company) ([@bib70]) intraperitoneally (i.p.). If Hy10 B cells were co-transferred with OT-II, hosts were immunized with 50 μg of HEL-OVA or DEL-OVA ([@bib70]) mixed 1:1 with Sigma Adjuvant System (SAS, previously Sigma RIBI adjuvant) for a total volume of 200 μL. Animals were immunized with 100 μg NP-(20-29)-CGG (Biosearch technologies) mixed with 1:1 Alum (Alhydrogel) for a total of 200 μL volume. 2 × 10^8^ SRBC (Colorado Serum Company) were injected in a volume of 300 μL. Tamoxifen (Sigma) was dissolved in Corn Oil (Sigma) at 20 mg/mL and injected at 2 mg/20 g mouse i.p. TAM diet (Envigo) containing chow replaced normal chow when indicated.

### Flow Cytometry {#sec4.4.6}

Cells were stained on ice, in 96 round bottom plates in PBS supplemented with 2% FBS and 1mM EDTA. The following antibodies were used: B220 APC-CY7 or BV785 (clone RA3-6B2), IgD FITC (clone 11-26c.2a), GL-7 Pacific Blue (clone GL7), FAS PE-CY7 (clone Jo2), CD38 AlexaFluor647 (clone 90), CD45.1 PERCP-CY5.5, APC (clone A20), CD45.2 BV605, APC-CY7 (clone 104), HVEM PE (clone LH1), BTLA AlexaFluor 647 (8F4), Ephrin-B1 Biotin (polyclonal, R&D), CXCR4 Biotin (clone 2B11/CXCR4), CD86 AlexaFluor647 (clone GL-1), IgG1 FITC (clone RMG1-1), CD138 BV421 (clone 281-2), CD73 PERCP-CY5.5 (clone TY/11.8), CD4 PE-CY7 (clone GK1.5), TCRβ Pacific Blue (clone H57-597), CXCR5 BV605 (clone L138D7), PD-1 PE or FITC (clone 29F.1A12), CD40L PE (clone MR1), Vα2 PERCP-CY5.5 (clone B20.1), Active caspase-3 (clone C92-605), Fixable viability dye eFluor780 (eBioscience). NP-47-PE (Biosearch technologies). For intracellular staining, cells were fixed and permeabilized using BD Cytofix/Cytoperm kit. EdU was detected with Click-IT Plus EdU kit (Invitrogen). Data were collected on a BD LSRII and analyzed on FlowJo Software.

### qPCR and RNA Sequencing {#sec4.4.7}

*Hvem* primers F: GGAGCTGGGATAGCTGGATTC R: TCTCCTGTTGTTCCTGGAAAGG, *Il21* primers F: GCTCCACAAGATGTAAAGGG R: TTATTGTTTCCAGGGTTTGA. Cells were sorted using BD FACSAria II. 10^4^ cells or greater were sorted for qPCR and 5 × 10^4^ cells were sorted for RNA-sequencing. RNA sequencing was prepared using Ovation RNA-seq System V2 from Nugen, KAPA Hyper prep labeling kit, NEXTflex DNA barcodes Adapter kit from Bioo Scientific. 100 bp paired end was run on HiSeq4000 at UCSF Institute for Human Genetics. Data were run through STAR alignment and Deseq2.

### GSEA and Gene Ontology {#sec4.4.8}

GSEA analysis (v3.0) through the BROAD was performed using standard settings: 1000 number of permutations, collapsed data to gene symbols, permutation type phenotype, enrichment statistic weighted. Data for Rapamycin sensitive DEC205-WT GC B cell genes were accessed ([@bib20]) and significant genes, defined as padj \< 0.01 with \> 2-fold increased expression in untreated v. Rapa treated, were made into a manually curated gene list. Yu Myc targets UP was a premade GSEA gene list. Gene ontology was performed using Enrichr platform ([@bib31]).

### NP V~H~186.2 Mutation Analysis {#sec4.4.9}

For bulk GC sequencing: PCR reaction 1. PCR1 F primer: CATGGGATGGAGCTGTATCATGC R primer: CTCACAAGAGTCCGATAGACCCTG PCR2 (nested) F primer: GGTGACAATGACATCCACTTTGC R primer: GACTGTGAGAGTGGTGCCTTG and the blunt end cloned into TOPO vector. Plates were sent to TacGen for plasmid prep and Sanger sequencing ([@bib3]). For single cell sequencing: NP^+^ cells were sorted into lysis buffer and frozen in 96-well round bottom plates. Nested PCR with primers and sent for sequencing. 186-EF: GTATCATGCTCTTCTTGGCAGC 186-IF: ACAGTAGCAGGCTTGAGGTCTG 186-IR: CCCAATGACCCTTTCTGACTC 186-ER: TGAGGATGTCTGTCTGCGTCA ([@bib68]). Data were analyzed using IgBLAST and the frequency of W33L were counted in non-frame shifted IGHV1-72^∗^01 sequences.

### Tfh Cell CD40L Surface Mobilization {#sec4.4.10}

Tfh cells were generated by transferring OT-II into WT mice on day −1 and immunizing retro-orbitally with 2 × 10^8^ SRBCs (Colorado Serum Company) conjugated to 10 μg (0.85 mg/mL) HEL-OVA and mixed with 150 μg (1 mg/mL) poly I:C (GE Healthcare) pre-heated for 10 min at 60°C in a total volume of 350 μL on day 0. On day 3, spleens were harvested and CD4^+^ T cells were isolated through negative selection by depletion with anti-CD8a biotin, anti-CD11c biotin, and anti-CD19 biotin antibodies and EasySep Mouse Streptavidin RapidSpheres (Stemcell) in complete RPMI. For B cells, spleens were harvested from WT or *Hvem*^−/−^ mice. Splenocytes were CTV labeled at 0.5 μM and pulsed with 10 μM, 2 μM, 0.4 μM, or 0.08 μM OVA 323-339 peptide (GenScript) antigen or no antigen for 2 h at 37°C. The splenocytes were all washed three times and 8 × 10^5^ splenocytes were combined with 4 × 10^5^ CD4^+^ T cells in a 96-well round bottom plate. To facilitate detection of surface exposed CD40L, the cells were incubated in the presence of 1 μg/mL anti-CD40L PE antibody as previously described ([@bib21], [@bib29]). After 30 or 60 min incubation at 37°C, T cells were harvested, stained, and analyzed on the LSRII flow cytometer. Anti-CD11c biotin antibody and EasySep Mouse Streptavidin RapidSpheres (Stemcell) were used to deplete dendritic cells in two experiments with no differing results.

### Assessment of BCR Clonality by PCR {#sec4.4.11}

Assessment of clonality by PCR of J558 heavy chain, and κ light chains from genomic DNA from 2 × 10^4^ FACS sorted GC B cells from 8 week old *Btla*^f/f^ *Cd4*^Cre^ and *Btla*^f/f^ control chimeras ([@bib16], [@bib40]). Primers:V~H~J558 CGAGCTCTCCARCACAGCCTWCATGCARCTCARCJ~H~4 CGAGCTCTCCARCACAGCCTWCATGCARCTCARCV~κ~ GGCTGCAGSTTCAGTGGCAGTGGRTCWGGRACJ~κ~5 GGCTGCAGSTTCAGTGGCAGTGGRTCWGGRAC

### Human CD4^+^ T Cell Isolation, Stimulation, And Transfection {#sec4.4.12}

Primary human CD4^+^ T cells were isolated using the RosetteSep Human CD4^+^ T Cell Enrichment Cocktail (StemCell Technologies) as per the manufacturer's instructions from leukocyte cones provided by UK National Health Service Blood and Transplant. Use of leukapheresis products at the University of Oxford was approved by the Non-Clinical Issue division of the National Health Service (REC 11/H11/7), and the use of human tonsil tissue was approved under the Oxford Radcliffe Biobank (ORB) research tissue bank ethics, reference 09/H0606/5+5. Isolated cells were cultured in RPMI-1640 supplemented with 10% FCS, 4 mM L-glutamine, 10 mM HEPES, 1% non-essential amino acid solution (GIBCO), and 1% penicillin-streptomycin solution (GIBCO) at 37°C, 5% CO~2~ for between 24 and 72 h before stimulating. Cells were diluted to 1 × 10^6^/mL in supplemented RPMI-1640 containing 50 U/mL recombinant IL-2 (PeproTech) and anti-human CD3/CD28 Dynabeads (GIBCO) at 1 × 10^6^/mL. Cells were cultured for 3 days before the beads were removed by magnetic separation and the medium replaced with fresh supplemented RPMI-1640 + 50 U/mL IL-2. Cells were cultured for a further 4 days with medium replaced and cells diluted to 1 × 10^6^/mL as required.

Human BTLA was cloned into pGEM-SnapTag vector. This vector was used to produce mRNA *in vitro* using the mMESSAGE mMACHINE T7 Transcription Kit (Thermo Fisher Scientific) as per the manufacturer's instructions. Transfection was performed 24 h before imaging. Cells were washed 3 times with OptiMEM (GIBCO) at room temperature and resuspended at 2.5 × 10^6^ cells/100 μl. 2.5 -- 7.5 μg mRNA encoding WT or mutant BTLA-SNAP-tag was added to 2.5 × 10^6^ cells, which were gently mixed, transferred to a Gene Pulser cuvette (BioRad) and pulsed for 2 ms at 300 V in an ECM 830 Square Wave Electroporation System (BTX). Cells were then immediately transferred to supplemented RPMI-1640 at 1 × 10^6^/mL and cultured for 24 h. The amount of mRNA used was optimized for each T cell donor and mRNA preparation by performing multiple transfections with titrated mRNA amounts, then assessing total BTLA expression after 24 h by staining with AlexaFluor 647-conjugated anti-BTLA (BioLegend, 344520) and comparing to Quantum AlexaFluor 647 MESF calibration beads (Bangs Laboratories) by flow cytometry. Conditions giving ∼10,000 transfected BTLA/cell were selected for imaging.

### Human Tfh Cell Isolation {#sec4.4.13}

Human Tfh cells were isolated from tonsils provided by UK National Health Service Blood and Transplant. Tissue was kept on ice prior to use and processed within 3 h of surgery. Tonsils were washed in ice-cold Hank's balanced salt solution (HBSS; GIBCO) supplemented with 2% FCS, 5% penicillin-streptomycin solution (GIBCO), and 500 μg/mL normocin (Invivogen). Whole tonsils were partially submerged in cold, supplemented HBSS and dissected into pieces 1--5 mm in size using a sterile scalpel. Tissue fragments were separated into multiple 70 μm cell strainers and crushed using a 20 mL syringe plunger, then washed with cold, supplemented HBSS. Strained samples were pooled and passed through a 40 μm cell strainer then pelleted at 400 g for 10 min and resuspended in 15 mL cold, supplemented HBSS. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Paque density gradient centrifugation. Total CD4^+^ T cells were isolated from the PBMC fraction using the EasySep CD4^+^ isolation kit (StemCell Technologies) and kept on ice in supplemented HBSS. Cells were immediately stained with anti-CXCR5 conjugated to either AlexaFluor 488 (BD Biosciences, 558112) or PE/Cy7 (BioLegend, 356923) depending on the downstream application, washed, and the CXCR5^high^ population sorted using a FACSAria III cell sorter (BD Biosciences). Isolated Tfh cells were resuspended at 5 × 10^6^/mL in supplemented RPMI-1640 and cultured for 3 h at 37°C, 5% CO~2~ before being used for imaging. A small number of cells were retained and stained with anti-CXCR5 and anti-PD1 conjugated to AlexaFluor 488 (BioLegend, 329935) or AlexaFluor 647 (BioLegend, 329910), washed, and analyzed by flow cytometry to confirm the purity of the CXCR5^high^ PD1^+^ population.

### Quantification of BTLA and HVEM Surface Expression {#sec4.4.14}

Isolated whole CD4^+^ populations or isolated Tfh cells were stained with with AlexaFluor 647-conjugated anti-BTLA (BioLegend, 344520) and compared to Quantum AlexaFluor 647 MESF calibration beads (Bangs Laboratories) by flow cytometry. HVEM levels on B cells were determined by staining PBMCs from whole blood with anti-CD19-PE-Cy7 (BD Biosciences; 560911), anti-CD38-AlexaFluor 488 (BioLegend; 303511), anti-CD27-BrilliantViolet421 (BioLegend; 356417), anti-CD20-PE (BioLegend; 302305), and anti-HVEM-AlexaFluor 647 (BD Biosciences; 564411). B cell subsets were gated as follows: Activated (CD19^+^ CD20^+^ CD27^+^ CD38^+^), Memory (CD19^+^ CD20^+^ CD27^+^ CD38^-^), immature/transitional (CD19^+^ CD20^+^ CD27^-^ CD38^+^), and plasmablasts (CD19^+^ CD20^-^ CD27^+^ CD38^+^). HVEM intensity on each cell subset was converted to absolute protein numbers by reference to Quantum AlexaFluor 647 MESF calibration beads (Bangs Laboratories). Based on the mean HVEM expression on activated B cells of ∼35,000/cell, minimum surface density was estimated at ∼35 molecules/μm^2^ assuming an upper limit of ∼1000 μm^2^ total area.

### Supported Lipid Bilayer Preparation and Use {#sec4.4.15}

Supported lipid bilayers (SLB) were prepared as described previously ([@bib14]). Briefly, micelles of 1,2-dioleoyl-sn-glycero-3-phosphocholine (Avanti Polar Lipids Inc.) supplemented with 12.5% 1,2-dioleoyl-sn-glycero-3-\[(N-(5-amino-1-carboxypentyl) iminodiacetic acid) succinyl\]-Ni (Avanti Polar Lipids Inc.) were flowed onto glass coverslips hydroxylated with piranha solution, plasma cleaned, and affixed with adhesive 6-lane chambers (Ibidi). SLBs were blocked and washed, then incubated with recombinant His-tagged proteins of interest (produced in-house with the exception of HVEM-Fc-His, which was a gift from Prof. Simon Davis, University of Oxford) at the requisite concentrations to achieve the desired density: 30 molecules/μm^2^ for UCHT1-FaB, 200 molecules/μm^2^ for ICAM1, 100 molecules/μm^2^ for CD80, 35 molecules/μm^2^ for HVEM-Fc-His, and 100 molecules/μm^2^ for CD40. The specific combination of unconjugated proteins or proteins conjugated to different dyes (AlexaFluors 405, 488, 568, and 657) was varied to suit the demands of each experiment. Within 2 h of preparation, SLBs were pre-warmed to 37°C and cells were infused into the SLB chambers at ∼5 × 10^5^/lane for CD4^+^ cells or ∼1 × 10^5^/lane for Tfh cells. Samples were either incubated for 3 or 15 min at 37°C then fixed with warm 4% para-formaldehyde in PHEM buffer (60 mM PIPES, 25 mM HEPES, 10 mM EGTA, 2 mM MgCl~2~, pH 6.9) for 10 min, or imaged live. In experiments involving labeling of transfected BTLA-SNAP-tag, cells were incubated with 0.5 μM SNAP-Cell 647-SiR ligand (New England BioLabs) in supplemented RPMI-1640 for 30 min at 37°C, washed 3 times, and incubated for a further 30 min prior to addition to SLBs.

### Immunofluorescence Staining {#sec4.4.16}

Fixed cell samples were exposed to a second round of fixation in PHEM buffer with 2% PFA and 3% BSA (bovine serum albumin) for 10 min at room temperature in order to reduce non-specific adsorption of probing antibodies to the coverslip. Samples were washed 3 times with PHEM buffer, permeabilized with 0.1% saponin in PHEM buffer for 15 min, then washed 3 more times with PHEM buffer. Samples were then quenched with 100mM glycine for 20 min and blocked with 6% BSA in PHEM buffer for 1 h before washing 3 times with PHEM buffer. Samples were then incubated with the appropriate primary rabbit antibody (anti-SHP1, Santa Cruz Biotechnology, sc-287; anti-SHP2, Santa Cruz Biotechnology, sc-280; anti-pY493 ZAP70, Cell Signaling Technology, 2704; anti-pT538 PKCθ, Cell Signaling Technology, 9377) in PHEM buffer with 0.02% saponin, 3% BSA for 1 h. Washing was performed 3 times with PHEM buffer, 0.1% saponin, 3% BSA with 2 min between each wash, before incubating with goat anti-rabbit F(ab')2 conjugated to AlexaFluor 568 (ThermoFisher Scientific, A-21069) in PHEM buffer with 0.02% saponin, 3% BSA for 45 min. Samples were finally washed 5 times with PHEM buffer, 0.1% saponin, 3% BSA with 2 min between each wash before imaging. A sample stained using only secondary antibody was included in each experiment as a background control.

### TIRF and Confocal Imaging {#sec4.4.17}

TIRF imaging was performed on an Olympus cellTIRF-4Line system using a 150x (NA 1.45) oil objective. Imaging of live samples was performed at 37°C, and of fixed samples at room temperature. Confocal imaging was performed on a 37°C-controlled Olympus FV1200 confocal microscope using a 20x (NA 0.75) air objective.

### Image Analysis {#sec4.4.18}

All image analysis was performed using the ImageJ software. Thresholded IRM images were used to define the contact area of each cell, and all pixels therein used to calculate the mean fluorescence intensity (MFI) for a given channel. Pearson colocalization coefficients (PCCs) were also calculated only for IRM-defined contact areas using the Coloc 2 plugin to perform pixel intensity correlation between channels. Identification and tracking of cells for comparison of adhesion and movement was performed using the TrackMate plugin, with total cells detected from bright field images and those forming contacts identified through IRM images. Cells were qualitatively assigned as forming synapses or kinapses based on the relative centrality and symmetry of the predominant UCHT1 and ICAM1 signals. Synapses were defined as having approximately central UCHT1 accumulations completely surrounded by a ring of ICAM1; kinapses as having a highly polarized UCHT1 accumulation with ICAM1 adjacent but not surrounding. Cells not fitting either category were defined as unassigned.

### *In Situ* Analysis of Interaction of SHP1 and SHP2 with PD-1 {#sec4.4.19}

Supported lipid bilayers presenting relevant ligands were prepared as described above. Biotin-CAP-phosphatidylethanolamine was used at a 0.04 molar percentage to that of dioleoylphosphatidylcholine (DOPC). Monobiotinylated Okt3 (anti-CD3 antibody, from Ebiosciences) was used at 0.5 μg/mL. The following ligands were presented on the bilayer by means of coordination chemistry between DOGS-NTA and poly-Histidine tag: 12×-His ICAM1 ectodomain at ∼200 molecules/μm^2^; 12×-His CD58 ectodomain at ∼300 molecules/μm^2^; and 12×-His PDL1 ectodomain at ∼300 molecules/μm^2^. Freshly isolated human CD8^+^ T cells were electroporated with mRNA encoding PD-1 GFP or PD-1 Y248F GFP and cultured for ∼8 h ([@bib74]). Cells were introduced into the flow-cells containing lipid bilayers at 37°C and fixed after 10 min by flowing in pre-warmed 2% EM-grade formic acid in PBS. SHP1/2 staining was performed as described above. Images were acquired on a Nikon Eclipse Ti inverted fluorescence microscope using an Apo TIRF 100× 1.49 NA oil objective. Diode lasers (488 nm, 561 nm and 641 nm, from Coherent) were used for TIRF illumination at the plane of bilayer. An AOTF (from Solamere Technologies) was used for choosing appropriate excitation wavelengths. A xenon arc lamp (from Newport) filtered at 490 nm was used for reflection imaging of cell contacts with the bilayer. Nikon perfect focus system® was used to achieve consistent illumination and also to compensate for axial chromatic aberration. NIS-Elements software (from Nikon) was used for hardware control of the microscope, filter and shutter wheels, AOTF, and the EMCCD camera (Andor DU-897 X-4654) during image acquisition. EMCCD camera was operated in the normal gain mode and well under saturation. Custom written macros were used for automated image analysis in ImageJ 1.44o (from NIH). Cell-boundaries were defined based on segmented ('Default' algorithm in ImageJ) reflection images. Background subtracted images were used for calculating average fluorescence intensity from each cell. PCC values between thresholded green and far-red channels ('MaxEntropy' algorithm in ImageJ) were calculated for each cell to quantitatively measure the extent of colocalization. Cluster statistics were computed using the 'Analyze Particles' routine in ImageJ after thresholding the images using the 'MaxEntropy' algorithm. Statistical significance was assessed by Mann-Whitney test using the GraphPad Prism5 software.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

All statistical tests were done with GraphPad Prism software. The appropriate statistical test for each experiment is noted in the figures.

Data and Code Availability {#sec4.6}
--------------------------

Raw and processed data files for RNA sequencing analysis have been deposited in the NCBI Gene Expression Omnibus under accession number GEO: [GSE130095](ncbi-geo:GSE130095){#intref0060}.
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